Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials

Journal of Clinical Pharmacy and Therapeutics

Volumn 31, Issue 6, 2006, Pages 565-576

  Chen, L C ^a   Ashcroft, D M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cerebrovascular event; COX 2 inhibitor; Drug safety; Meta analysis; Pharmacovigilance; Stroke; Systematic review

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; LUMIRACOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; ROFECOXIB; VALDECOXIB;

ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; HEART INFARCTION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; THROMBOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CEREBROVASCULAR ACCIDENT; CYCLOOXYGENASE INHIBITORS; HUMANS; NAPROXEN; RANDOMIZED CONTROLLED TRIALS; RISK;

EID: 33751378367     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2006.00774.x     Document Type: Article

References (61)

1. Breckenridge A, Woods K, Raine J (2005) Monitoring the safety of licensed medicines. Nature Reviews Drug Discovery, 4, 541-543.
2. Eisenberg RS (2005) Learning the value of drugs-is rofecoxib a regulatory success story? New England Journal of Medicine, 352, 1285-1287.
3. Sciulli MG, Capone ML, Tacconelli S, Patrignani P (2005) The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. Pharmacological Reports, 57 (Suppl.), 66-85.
4. Bombardier C, Laine L, Reicin A et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. Vioxx Gastrointestinal Outcomes Research (VIGOR). New England Journal of Medicine, 343, 1520-1528.
5. Bresalier RS, Sandler RS, Quan H et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New England Journal of Medicine, 352, 1092-1102.
6. Velentgas P, West W, Cannuscio CC, Watson DJ, Walker AM (2006) Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmacoepidemiology and Drug Safety, 15, 641-652.
7. Vonkeman HE, Brouwers JR, van de Laar MA (2006) Understanding the NSAID related risk of vascular events. British Medical Journal, 332, 895-898.
8. Aldington S, Shirtcliffe P, Weatherall M, Beasley R (2005) Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis. New Zealand Medical Journal, 118, U1755.
9. Aldington S, Shirtcliffe P, Weatherall M, Beasley R (2005) Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy. New Zealand Medical Journal, 118, U1684.
10. Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R (2006) Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. Journal of The Royal Society of Medicine, 99, 132-140.
11. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet, 364, 2021-2029.
12. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C (2006) Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. British Medical Journal, 332, 1302-1308.
13. Matchaba P, Gitton X, Krammer G et al. (2005) Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials ≥1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Clinical Therapeutics, 27, 1196-1214.
14. White WB, Strand V, Roberts R, Whelton A (2004) Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. American Journal of Therapeutics, 11, 244-250.
15. Andersohn F, Schade R, Suissa S, Garbe E (2006) Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke. A nested case-control study. Stroke, 37, 1725-1730.
16. Pharmaceutical Research and Manufacturers of America. (2002) Clinical study results database. http://www.clinicalstudyresults.org.
17. Jadad AR, Moore RA, Carroll D et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials, 17, 1-12.
18. Sweeting MJ, Sutton AJ, Lambert PC (2004) What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine, 23, 1351-1375.
19. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Statistics in Medicine, 21, 1539-1558.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. British Medical Journal, 327, 557-560.
21. Whelton A, White WB, Bello AE, Puma JA, Fort JG (2002) Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. American Journal of Cardiology, 90, 959-963.
22. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ (2002) Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. Journal of American Medical Association, 287, 64-71.
23. Kivitz AJ, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey C (2004) Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Alimentary Pharmacology and Therapeutics, 19, 1189-1198.
24. Lehmann R, Brzosko M, Kopsa P et al. (2005) Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib. Current Medical Research and Opinion, 21, 517-526.
25. Berenbaum F, Grifka J, Brown JP et al. (2005) Efficacy of lumiracoxib in osteoarthritis: a review of nine studies. Journal of International Medical Research, 33, 21-41.
26. Geusens P, Alten R, Rovensky J et al. (2004) Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis. International Journal of Clinical Practice, 58, 1033-1041.
27. Levin B (2005) Celecoxib in Adenoma Prevention - The PreSAP Trial. FDA Advisory Committee on COX-2 Inhibitors and NSAIDs, February 16-18. http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4090S1_09_FDA-Levin_files/ frame.htmslide0714.htm (Accessed April 2005).
28. Solomon SD, McMurray JJ, Pfeffer MA et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New England Journal of Medicine, 352, 1071-1080.
29. Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM (2002) Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. European Journal of Gastroenterology and Hepatology, 14, 1101-1111.
30. White WB, Faich G, Whelton A et al. (2002) Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. American Journal of Cardiology, 89, 425-430.
31. Farkouh ME, Kirshner H, Harrington RA et al. (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet, 364, 675-684.
32. Merck Research Laboratories. (2005) FDA Advisory Committee Meeting background document on etoricoxib. http://origin.www.fda.gov/ohrms/dockets/ac/ 05/briefing/2005-4090B2_01_Merck-Etoricoxib.pdf (Accessed April 2005).
33. Ioannidis JP (1998) Contopoulos-Ioannidis DG. Reporting of safety data from randomised trials. Lancet, 352, 1752-1753.
34. Tanne JH (2005) Journal criticises Vioxx study for omitting three heart attacks. British Medical Journal, 331, 1423.
35. Tanne JH (2006) NEJM stands by its criticism of Vioxx study. British Medical Journal, 332, 505.
36. Berlin JA, Colditz GA (1999) The role of meta-analysis in the regulatory process for foods, drugs, and devices. Journal of American Medical Association, 281, 830-834.
37. Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG (2005) Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clinical Trials, 2, 209-217.
38. Clarke MJ, Stewart LA (2001) Obtaining individual patient data from randomised controlled trials. In: Egger M, Smith GD, Altman GD, eds. Systematic reviews in health care: meta-analysis in context. 2nd edn. London: BMJ Publishing Group, 109-121.
39. Brophy JM (2005) Celecoxib and cardiovascular risks. Expert Opinion on Drug Safety, 4, 1005-1015.
40. Pfizer Inc. (1998) Protocol N49-96-02-023: a double-blind, placebo controlled, randomized comparison study of the efficacy and safety of SC-58635 100 mg, 200 mg and 400 mg BID and naproxen 500 mg BID in treating the signs and symptoms of rheumatoid arthritis. http://www.clinicalstudyresults.org/documents/ company-study_79_19.pdf (Accessed December 2005).
41. Goldstein JL, Correa P, Zhao WW et al. (2001) Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. American Journal of Gastroenterology, 96, 1019-1027.
42. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS (2001) Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scandinavian Journal of Rheumatology, 30, 11-18.
43. Pfizer Inc. (2001) Protocol I49-98-02-96: Successive Celecoxib Efficacy and Safety Studies in osteoarthritis (SUCCESS-1). http://www. clinicalstudyresults.org/documents/company-study_79_5.pdf (Accessed December 2005).
44. Pfizer Inc. (2004) Protocol IQ5-97-02-001: a double-blind, randomized, placebo-controlled, comparative study of celecoxib (SC-58635) for the inhibition of progression of Alzheimer's disease. http://www.clinicalstudyresults.org/ documents/company-study_76_0.pdf (Accessed December 2005).
45. Pfizer Inc. (2005) Protocol A3191006: a one-year, double blind, parallel group study to compare the tolerability of celecoxib 200 mg once daily versus diclofenac 50 mg twice daily in elderly patients with osteoarthritis of the hip or knees (coxarthrosis/gonarthrosis). http://www.clinicalstudyresults.org/ documents/company-study_79_21.pdf (Accessed December 2005).
46. Pallay RM, Seger W, Adler JL et al. (2004) Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scandinavian Journal of Rheumatology, 33, 257-266.
47. Merck Research Laboratories. (2005) FDA Advisory Committee Meeting background information, ARCOXIA™ (etoricoxib tablets). http://origin.www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B2_01_Merck- Etoricoxib.pdf (Accessed May 2005).
48. Beaulieu A, Rovensky J, Philipp T. (2005) Lumiracoxib is effective in the long-term management of pain associated with rheumatoid arthritis. Annals of the Rheumatic Diseases, 64(Suppl. 3), 426.
49. Villalba ML (1998) NDA executive summary: vioxx, excerpts from primary review of NDA 21-042 - osteoarthritis. Food and Drug Administration. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1_05_F-FDA-Tab-D-1. pdf (Accessed May 2005).
50. Laine L, Harper S, Simon T et al. (1999) A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology, 117, 776-783.
51. Cannon GW, Caldwell JR, Holt P et al. (2000) Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis and Rheumatism, 43, 978-987.
52. Saag K, van der HD, Fisher C et al. (2000) Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group. Archives of Family Medicine, 9, 1124-1134.
53. Villalba ML (2001) Medical Officer Review: NDA 21-042 and NDA 21-052 (rofecoxib tablets and rofecoxib oral Solution). Food and Drug Administration. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1_09_J-FDA-Tab-F-1. pdf (Accessed May 2005).
54. Geba GP, Polis AB, Najarian DK, Dixon ME, Storms WW, Weaver AL (2001) Onset of efficacy and patient assessment of clinical response in osteoarthritis (OA): comparison of rofecoxib to nubumetone. Journal of the American Geriatrics Society, 49, S126.
55. Lisse JR, Perlman M, Johansson G et al. (2003) Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Annals of Internal Medicine 139, 539-546.
56. Thal LJ, Ferris SH, Kirby L et al. (2005) A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology, 30, 1204-1215.
57. Pfizer Inc. (2002) Protocol I91-99-02-063: a multicenter, double-blind, randomized parallel group comparison study of the efficacy and safety over 6 months of therapy, and joint X-ray changes over 12 months of therapy of valdecoxib 10 mg and 20 mg once daily and diclofenac 75 mg SR twice daily in treating the signs and symptoms of osteoarthritis of the knee and/or hip. http://www.clinicalstudyresults.org/documents/company-study_83_0.pdf (Accessed December 2005).
58. Weaver A, Bensen W, Espinoza L, Riley W, Recker DP (2002) Valdecoxib provides improved efficacy in patients with rheumatoid arthritis (RA) even when administered concomitantly to patients already taking DMARDS or low dose corticosteroids [abstract 851]. Arthritis and Rheumatism, 46(Suppl.), S336.
59. Bensen W, Weaver A, Espinoza L et al. (2002) Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology, 41, 1008-1016.
60. Kivitz A, Eisen G, Zhao WW, Bevirt T, Recker DP (2002) Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. The Journal of Family Practice, 51, 530-537.
61. Pavelka K, Recker DP, Verburg KM (2003) Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Rheumatology, 42, 1207-1215.